Compare IART & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IART | CMPS |
|---|---|---|
| Founded | 1989 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 696.8M | 778.7M |
| IPO Year | 1996 | 2020 |
| Metric | IART | CMPS |
|---|---|---|
| Price | $9.32 | $5.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $14.50 | ★ $27.14 |
| AVG Volume (30 Days) | 769.4K | ★ 2.4M |
| Earning Date | 05-04-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.70 | $2.25 |
| 52 Week High | $22.27 | $8.90 |
| Indicator | IART | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 38.51 | 39.91 |
| Support Level | N/A | $4.78 |
| Resistance Level | $14.14 | $7.02 |
| Average True Range (ATR) | 0.42 | 0.41 |
| MACD | 0.06 | -0.14 |
| Stochastic Oscillator | 58.33 | 29.96 |
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.